Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Efficacy of XJ-MK-002 in Cancer Therapy-Induced Thrombocytopenia
NCT07110090Phase 1Recruiting
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Start
- Aug 2025
- Primary completion
- Jun 2026
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label trial of XJ-MK-002 in Thrombocytopenia (3 arms), sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Primary endpoint: Incidence and severity of adverse events at 28 days. Started Aug 2025; status: recruiting.
02
Drugs
XJ-MK-002
03
Conditions
Thrombocytopenia
Beyond the preview
Go deeper on NCT07110090.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07110090.